Monoclonal antibodies against carcinoembryonic antigens, and their use

Monoclonal antibodies targeting CEA with defined CDR sequences address the limitations of existing CEA detection methods by enhancing specificity and sensitivity, facilitating effective cancer diagnosis and treatment.

JP7949041B2Active Publication Date: 2026-11-11エムエービー バイオテック インコポーレイテッド
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024526885
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2022-11-04
Publication Date
2026-11-11
Estimated Expiration
2042-11-04

AI Technical Summary

Technical Problem

Existing methods for detecting and treating cancers associated with carcinoembryonic antigen (CEA) expression are limited by low specificity and sensitivity, particularly in early stages, and CEA's overexpression in non-cancer conditions complicates its use as a general cancer screening tool.

Method used

Development of monoclonal antibodies (mAbs) and antigen-binding fragments that specifically target CEA, including ADx-CEA, with defined CDR sequences, for diagnostic and therapeutic applications, enabling precise detection and treatment of CEA-expressing cancers.

Benefits of technology

The ADx-CEA antibodies demonstrate high sensitivity and specificity in detecting CEA in various cancer types, particularly in early stages, and provide therapeutic efficacy by targeting CEA-expressing cells, thereby aiding in cancer diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007949041000008
    Figure 0007949041000008
  • Figure 0007949041000009
    Figure 0007949041000009
  • Figure 0007949041000010
    Figure 0007949041000010
Patent Text Reader

Abstract

The present invention provides anti-carcinoembryonic antigen (CEA) antibodies for use in detecting CEA, treating disorders associated with CEA expression, diagnosing cancers characterized by aberrant CEA expression, and predicting the efficacy of cancer chemotherapy. Anti-CEA antibodies, antibody fragments, monoclonal antibodies, antibody conjugates, compositions comprising the described antibodies, and methods of their use are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Application No. 63 / 336,676 filed on 29 April 2022 and U.S. Application No. 63 / 275,998 filed on 5 November 2021, the entire contents of which are incorporated herein by reference for any purpose.

[0002] The present invention relates to monoclonal antibodies (mAbs) and antigen-binding fragments thereof that conjugate carcinoembryonic antigen (hereinafter also referred to herein as "CEA"). Accordingly, the present invention encompasses the use of these mAb antibodies, in particular for detecting CEA, and for diagnosing and treating diseases and conditions associated with, or known to be associated with, abnormal CEA expression, such as cancer. [Background technology]

[0003] Carcinoembryonic antigen (CEA) belongs to a family of immunoglobulins with a molecular weight of approximately 180,500 daltons (180 kDa). CEA is a protein present in certain tissues of a developing baby (fetus), but its expression decreases to very low levels by the time the baby is born. In adults, CEA is usually present in the blood at very low levels, but it can be elevated in certain types of cancer. Also known as CEACAM5 or CD66e, CEA was discovered in malignant tumors of the endodermal epithelium of the gastrointestinal tract and pancreas (Gold et al. The Journal of Experimental Medicine 122:467-481 (1965)). Since its discovery nearly 50 years ago, it has been shown to be overexpressed in the majority of human cancers (Gold et al. The Journal of Experimental Medicine 122:467-481 (1965), Blumenthal et al. BMC Cancer 7:1-15 (2007)). The function of CEA is to transport iron from the intestines, reticular endothelial system, and hepatocytes to all proliferating cells in the body. CEA may also have a physiological role as a granulocyte / pollen-binding protein (GPBP) involved in the removal of certain organic substances and allergens from serum, and may have a further role in stimulating cell proliferation. Human CEA is listed in the database UniProtKB / Swiss-Prot:P06731. CEA has immunoglobulin-like structural properties and contains many glycosylation modification sites (Beauchemin et al. Cancer and Metastasis Reviews 32:643-671 (2013)). CEA can also be overexpressed in several non-cancer-related conditions, such as inflammation, cirrhosis, peptic ulcers, ulcerative colitis, rectal polyps, emphysema, and benign breast disease, as well as in smokers. Therefore, CEA detection is generally considered not useful as a general cancer screening tool, but rather for evaluating the response to cancer treatment. See *The Dynamic Monitoring of CEA in Response to Chemotherapy and Prognosis of MCRC Patients*, Yu, et al., BMC Cancer. (2018) 18:1076, and *ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer*, Gershon et al., Journal of Clinical Oncology (2006) 24:5313. For example, if an individual is diagnosed with cancer, an initial baseline test for CEA may be performed. Subsequent serial CEA tests may be performed to monitor cancer progression as the individual receives treatment and / or as the individual is in remission. See Roberto et al. British Journal of Cancer (2021) 124:839. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Gold et al.The Journal of Experimental Medicine 122:467-481(1965) [Non-Patent Document 2] Blumenthal et al.BMC Cancer 7:1-15(2007) [Non-Patent Document 3] Beauchemin et al.Cancer and Metastasis Reviews 32:643-671(2013) [Non-Patent Document 4] The Dynamic Monitoring of CEA in Response to Chemotherapy and Prognosis of MCRC Patients.Yu,et al.BMC Cancer.(2018)18:1076 [Non-Patent Document 5] ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer.Gershon et al.Journal of Clinical Oncology(2006)24:5313 [Non-Patent Document 6] Roberto et al.British Journal of Cancer(2021)124:839 [Brief explanation of the drawing]

[0005] [Figure 1] This shows the heavy chain amplicon of ADx-CEA. [Figure 2] The NCBI_Ig Blast Tool_IMGT view of the ADx-CEA heavy chain is displayed. Single-letter coded amino acid positions, CDR positions, and the inclusion of gaps (*) to maximize homology within human IgHVDJs are from the IMGT database. The nucleotides and predicted protein sequences for the VDJ region of the heavy chain are shown below. [Figure 3] The NCBI_Ig Tool_IMGT blast sample of the ADx-CEA light chain is displayed. The single-letter encoded amino acid positions, CDR positions, and inclusion of gaps (*) to maximize homology within the human Ig KVJ are from the IMGT database. The nucleotides and predicted protein sequences for the K chain of the VJ region are shown below. [Figure 4] The SDS-PAGE analysis of the heavy and light chains of isolated ADx-CEA is shown. [Figure 5]Shows a Western blot analysis of CEA detected by isolated ADx-CEA. [Figure 6A] Shows a representative image of indirect immunofluorescence staining of CEA detected by isolated ADx-CEA that is punctately localized within vesicles. Figure 6A shows a phase contrast image. [Figure 6B] Shows a representative image of indirect immunofluorescence staining of CEA detected by isolated ADx-CEA that is punctately localized within vesicles. Figure 6B shows the immunofluorescence staining. [Figure 7] Shows a Western blot analysis of isolated ADx-CEA in a patient sample, where the patient has pancreatic cancer, compared to a control. [Figure 8] Shows IHC staining analysis by ADx-CEA in pancreatic cancer tissues of various stages. [Figure 9A] Shows the overall sensitivity and specificity of ADx-CEA. Figure 9A shows the sensitivity compared with Dako Omnis (Agilent) anti-CEA mAb (clone II-7). [Figure 9B] Shows the overall sensitivity and specificity of ADx-CEA. Figure 9B shows the specificity compared with the Dako antibody. [Figure 10A] Shows the sensitivity and specificity of ADx-CEA in early stages (I, II). Figure 10A shows the sensitivity compared with Dako Omnis (Agilent) anti-CEA mAb (clone II-7). [Figure 10B] Shows the sensitivity and specificity of ADx-CEA in early stages (I, II). Figure 10B shows the specificity compared with Dako Omnis (Agilent) anti-CEA mAb (clone II-7). [Figure 11A] Shows the sensitivity and specificity of ADx-CEA in late stages (III, IV). Figure 11A shows the sensitivity compared with Dako Omnis (Agilent) anti-CEA mAb (clone II-7). [Figure 11B]This shows the susceptibility and specificity of ADx-CEA in the later stages (III, IV). Figure 11B shows the specificity compared to Dako Omnis (Agilent) anti-CEA mAb (clone II-7). [Figure 12A] This shows data on soft agar coronary artery formation and related information. Figure 12A shows a representative low-magnification image of colony formation in untreated BxPC-3 cells. [Figure 12B] This shows data on soft agar coronary artery formation and related information. Figure 12B shows representative high-magnification images of colony formation in ADx-CEA-treated and untreated BxPC-3 cells. The well images are representative of three independent experiments. [Figure 12C] The soft agar coronary artery formation and related data are shown. Figure 12C shows the quantification of BxPC-3 colony counts after ADx-CEA treatment. [Figure 13A] This study shows CEA expression in various formalin-fixed, paraffin-embedded (FFPE) human tissues via IHC staining. CEA protein expression was validated using ADx-CEA in healthy tissues from healthy individuals and cancer patients, as well as in healthy and cancerous tissues. Cancerous tissues from the pancreas, colon, and liver showed positive membrane and cytoplasmic staining for CEA expression. Figure 13A shows the results for pancreatic tissue. [Figure 13B] This study shows CEA expression in various formalin-fixed, paraffin-embedded (FFPE) human tissues via IHC staining. CEA protein expression was validated using ADx-CEA in healthy tissues from healthy individuals and cancer patients, as well as healthy and cancerous tissues. Cancerous tissues from the pancreas, colon, and liver showed positive membrane and cytoplasmic staining for CEA expression. Figure 13B shows the results for colon tissue. [Figure 13C] This study shows CEA expression in various formalin-fixed, paraffin-embedded (FFPE) human tissues via IHC staining. CEA protein expression was validated using ADx-CEA in healthy tissues from healthy individuals and cancer patients, as well as in healthy and cancerous tissues. Cancerous tissues from the pancreas, colon, and liver showed positive membrane and cytoplasmic staining for CEA expression. Figure 13C shows the results for liver tissue. [Modes for carrying out the invention]

[0006] I. Definition In this application, the use of “or” means “and / or” unless otherwise specified. In the context of multiple dependent claims, the use of “or” means, only in substitution, to return to two or more preceding independent or dependent claims. The terms “comprising,” “including,” and “having” may be used interchangeably herein. According to the present invention, an “isolated” molecule is a molecule that has been removed from its natural environment. Therefore, the term “isolated” does not necessarily reflect the degree to which the molecule has been purified.

[0007] As used herein, CEA is also known as carcinoembryonic antigen-associated cell adhesion molecule 5, CECAM5, cell adhesion molecule 5, and CD66e. See, for example, UniProtKB / Swiss-Prot:P06731.

[0008] The term "antibody" as used herein is used in its broadest sense and encompasses a variety of antibody structures, including monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, as long as they exhibit the desired antigen-binding activity. Recombinant antibodies, chimeric antibodies, and humanized antibodies are also included.

[0009] An "antibody fragment" refers to a molecule other than the intact antibody, including a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments, but not limited to these, include Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments.

[0010] The term "antigen" refers to one or more molecules or parts of a molecule that can be bound by an antibody and can induce an animal to produce an antibody that can bind to the epitope of that antigen. An antigen may have one or more epitopes. The specific reaction mentioned above means that the antigen reacts very preferentially with its corresponding antibody and not with a large number of other antibodies that may be induced by other antigens. The binding of the antigen to the antibody must be above background levels.

[0011] The term "cancer" is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth. Cancer can be benign (also called a benign tumor), premalignant, or malignant. Cancer cells can be solid cancer cells or leukemic cancer cells.

[0012] The term "complementarity-determining region, or CDR," refers to the amino acid sequence that collectively determines the binding affinity and specificity of the native Fv region of the native immunoglobulin binding site. The light and heavy chains of immunoglobulins each have three CDRs.

[0013] The "class" of an antibody refers to the type of constant domain or constant region held by its heavy chain. Antibodies have five major classes: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0014] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used interchangeably herein and refer to antibodies having a structure substantially similar to that of a natural antibody or having a heavy chain containing an Fc region as defined herein.

[0015] A "human antibody" is one that is produced by a human or human cell, or possesses an amino acid sequence corresponding to the amino acid sequence of an antibody derived from a non-human source that utilizes the human antibody repertoire or sequences encoding other human antibodies. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues.

[0016] The term "variable region" or "variable domain" refers to a domain in the antibody heavy or light chain involved in the binding of an antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, and each domain contains four conserved framework regions (FRs) and three hypervariable regions (HVRs). (e.g., Kindt et al. Kuby Immunology, 6) th See ed., WH Freeman and Co., page 91 (2007). A single VH domain or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a specific antigen may be isolated using the VH domain or VL domain from the antigen-binding antibody to screen for a library of complementary VL domains or VH domains. See, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).

[0017] The "Human Consensus Framework" is a framework representing the most commonly present amino acid residues in the selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from subgroups of variable domain sequences. Generally, the sequence subgroups are those described in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In some embodiments, for VL, the subgroup is subgroup Kappa I, as described in Kabat et al. (see above). In some embodiments, for VH, the subgroup is subgroup III, as described in Kabat et al. (see above).

[0018] As used herein, the terms “hypervariable region” or “HVR” refer to each region of an antibody variable domain whose sequence is hypervariable (“complementarity-determining region” or “CDR”) and / or forms a structurally defined loop (“hypervariable loop”) and / or contains an antigen contact residue (“antigen contact”). Generally, an antibody contains six HVRs, three located in the VH region (H1, H2, H3) and three located in the VL region (L1, L2, L3).

[0019] "Isolated" antibodies are those separated from their natural environment. In some embodiments, antibodies are purified to a purity of 95% or more than 99%, as determined, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For an overview of methods for evaluating antibody purity, see, for example, Flatman et al., J.Chromatogr.B 848:79-87 (2007).

[0020] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies. That is, the individual antibodies constituting the population are identical and / or bind to the same epitope, except for, for example, naturally occurring mutations or variant antibodies that may arise during the production of the monoclonal antibody preparation, and such variants are generally present in small amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is against a single determinant on an antigen. Therefore, the modifier “monoclonal” indicates the characteristic of an antibody obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring antibody production by any particular method. For example, monoclonal antibodies used in accordance with the present invention may be produced by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of a human immunoglobulin locus, and such methods and other exemplary methods for producing monoclonal antibodies are described herein.

[0021] "Natural antibodies" refer to naturally occurring immunoglobulin molecules with various structures. For example, a natural IgG antibody is a heterotetrameric glycoprotein with approximately 150,000 daltons, composed of two identical disulfide-linked light chains and two identical heavy chains. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy chain domain or heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called a variable light chain domain or light chain variable domain, followed by a constant light (CL) domain. Based on the amino acid sequence of its constant domain, the light chains of an antibody can be assigned to one of two types called kappa (κ) and lambda (λ).

[0022] The "stage" of pancreatic cancer refers to the clinical stage as defined by the Joint Commission on Cancer (AJCC): 0, IA, IB, IIA, IIB, III, and IV, as defined by the AJCC. (Exocrine Pancreas. In: AJCC Cancer Staging Manual.8) th ed. New York, NY: Springer; 2017:337. As used herein, “early stage” pancreatic cancer refers to stages I and II, and “late stage” pancreatic cancer refers to stages III and IV.

[0023] Where used herein, “negative control” in relation to assays and detections referred herein refers to a control commonly used in the art by experts with respect to the type of assay being detected or assayed and the type of cancer. In the case of detecting CEA levels in human blood, for example, the CEA level in normal blood (plasma or serum) may be approximately 0–2.5 ng / mL. If the detected CEA level is higher than this level, it may be said to be higher than the negative control.

[0024] II. Compositions and Methods Anti-CEA antibodies, antibody fragments, monoclonal antibodies, antibody conjugates, compositions containing the described antibodies, and methods for using them are provided.

[0025] A. Exemplary anti-CEA antibody The following sequence listing provides the sequences of the antibody (ADx-CEA) disclosed and claimed herein. See Sequence IDs 1-12.

[0026] This specification provides antibodies and antibody fragments that specifically bind to human CEA, including ADx-CEA and its fragments and variants.

[0027] In a particular embodiment, an anti-CEA antibody and antibody fragment are provided, comprising a heavy chain variable region ("VH") including VH CDR1, CDR2, and CDR3, each containing SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region ("VL") including VL CDR1, CDR2, and / or CDR3, each containing one of SEQ ID NOs: 4, 5, and 6.

[0028] In some embodiments, antibodies comprising the following are provided: (a) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, (c) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, (d) LCDR1 containing (or not containing) the amino acid sequence of SEQ ID NO: 4, (e) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (f) LCDR3 containing the amino acid sequence of SEQ ID NO: 6, or (b) Heavy chain variable region (VH) and light chain variable region (VL), wherein VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7, and VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8, or (c) Heavy chain variable region (VH) and light chain variable region (VL), wherein VH includes the amino acid sequence of SEQ ID NO: 7 and VL includes the amino acid sequence of SEQ ID NO: 8, or (d) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, (c) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, (d) LCDR1 containing (or not containing) the amino acid sequence of SEQ ID NO: 4, (e) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (f) LCDR3 containing the amino acid sequence of SEQ ID NO: 6, as well as a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7, and VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8.

[0029] In some embodiments, the isolated antibody or antibody fragment described herein is a monoclonal antibody. In further embodiments, the isolated antibody or antibody fragment is a fully human antibody. In some embodiments, the isolated antibody or antibody fragment is an antibody fragment. In further embodiments, the antibody fragment is Fab, Fab', Fv, scFv, or (Fab')2. In some embodiments, the isolated antibody or antibody fragment is a full-length antibody. In some embodiments, the isolated antibody or antibody fragment includes an Fc region, and the Fc region of the antibody includes IgG1, IgG2, IgG3, IgG4, IgG4.1, or IgG4.2.

[0030] In some embodiments, compositions are provided that include an antibody or antibody fragment and a pharmaceutically acceptable carrier.

[0031] In some embodiments, the isolated antibody or antibody fragment is immobilized on a solid phase. In some embodiments, the isolated antibody or antibody fragment is detectably labeled. In some embodiments, the isolated antibody or antibody fragment is conjugated with a cytotoxic radionuclide. In some embodiments, the isolated antibody or antibody fragment is conjugated with a cytotoxic drug. In some embodiments, the isolated antibody or antibody fragment is conjugated with a cytotoxic protein.

[0032] In some embodiments, an isolated DNA sequence encoding an antibody or antibody fragment is provided. In some embodiments, the DNA includes SEQ ID NO: 11 or a fragment thereof. In some embodiments, the DNA includes SEQ ID NO: 12 or a fragment thereof. In some embodiments, the DNA includes SEQ ID NO: 11 or a fragment thereof and SEQ ID NO: 12 or a fragment thereof. In some embodiments, the DNA includes a sequence or fragment thereof that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 11. In some embodiments, the DNA includes a sequence or fragment thereof that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 12. In some embodiments, the DNA includes SEQ ID NO: 11 or a fragment thereof and SEQ ID NO: 12 or a fragment thereof. In some embodiments, the DNA includes a sequence or fragment thereof that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to sequence number 11, and a sequence or fragment thereof that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to sequence number 12.

[0033] In some embodiments, a vector is provided that includes a DNA sequence encoding an antibody or an antibody fragment.

[0034] In some embodiments, host cells are provided that have been transformed with a vector containing a DNA sequence encoding an antibody or an antibody fragment.

[0035] In some embodiments, a process for antibody production is provided, comprising culturing host cells transformed with a vector containing a DNA sequence encoding an antibody or antibody fragment, and isolating the antibody molecule.

[0036] In certain embodiments, the anti-CEA antibody or antibody fragment comprises an isolated antibody comprising VH which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7, and VL which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises (b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, (c) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (d) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, (e) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 5.

[0037] In some embodiments, the present invention includes a method for treating cancer, comprising administering a therapeutically effective amount of an anti-CEA antibody or antibody fragment described herein, or a composition thereof, or its DNA or vector, to a subject in need thereof. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer.

[0038] In certain embodiments, an immunoassay is provided for detecting a CEA antigen, comprising (a) contacting a sample with an antibody or antibody fragment described herein, such as ADx-CEA, in an effective bound amount, and (b) detecting the binding of the antibody to the CEA antigen, thereby detecting the antigen. In some embodiments, the assay is used to detect cancer cells expressing the CEA antigen. In some embodiments, the assay is used to detect solid tumors. In further embodiments, the cancer is colorectal cancer, liver cancer, gastric cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer.

[0039] In some embodiments, the present invention includes a method for detecting cancer in a subject, comprising contacting a sample isolated from a subject having cancer or suspected of having cancer with an antibody or antibody fragment described herein. In some embodiments, the cancer is a solid tumor. In further embodiments, the solid tumor is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer.

[0040] In certain embodiments, the present invention provides a kit for the immunohistochemical detection of solid tumor cancers containing cells expressing a CEA antigen, comprising: (a) an antibody or antibody fragment as described herein, such as ADx-CEA; and (b) a secondary antibody conjugated to a detectable label, which, when bound to the CEA antigen, binds to the antibody of (a) and can be detected. Alternatively, the secondary antibody is not conjugated to a detectable label, and instead, a label that binds to or interacts with the secondary antibody is used for detection. Methods for detecting CEA using the kit are encompassed.

[0041] In some embodiments, the present invention provides a method for determining the state of a solid tumor in a subject, comprising: (a) taking a sample from a subject having a solid tumor; (b) contacting the sample with an antibody or antibody fragment described herein, such as ADx-CEA, thereby forming a complex of the CEA antigen and the antibody or antibody fragment; (c) labeling the sample with a label specific to the antigen-antibody complex; and (d) detecting the presence of the antigen-antibody complex by detecting the label. In some embodiments, the sample is blood including whole blood, serum, or plasma, or tissue or cells.

[0042] In some embodiments, steps (a) to (d) described herein are repeated at a later point in time. In some embodiments, this point in time is after the subject has initiated therapy. In some embodiments, this point in time is after the subject has initiated a new or second (co)therapy. In some embodiments, the solid tumor cancer is colorectal cancer, liver cancer, gastric cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. In some embodiments, the solid tumor cancer is pancreatic cancer. In some embodiments, the subject has been diagnosed with cancer and is receiving or is about to receive therapy. In some embodiments, the sample is isolated from the subject before the initiation of therapy. In some embodiments, the sample is isolated from the subject after the initiation of therapy. In some embodiments, the therapy is chemotherapy or radiation. In some embodiments, the chemotherapy is erlotinib, fluorouracil, or oxaliplatin. In some embodiments, the therapy is surgery including Whipple treatment, distal pancreatectomy, and total pancreatectomy, radiotherapy, proton therapy, stereotactic radiotherapy (SBRT) or CyberKnife, immunotherapy, targeted therapy, or chemotherapy.

[0043] In some embodiments, the present invention includes a method for determining the status of a solid tumor cancer in a subject described herein, wherein a CEA level is determined, with a higher CEA level at a later time point indicating that the therapy is not completely effective, and the same or lower CEA antigen level at a later time point indicating that the therapy is at least partially effective. In some embodiments, the subject is in remission. In some embodiments, the method described herein is repeated at a time point after the subject has entered remission, and a CEA level is determined, with a higher CEA level at a later time point indicating that the cancer is no longer in remission, and the same or lower CEA level at a later time point indicating that the cancer remains in remission. In some embodiments, the method is an alternative to computed tomography.

[0044] In a particular embodiment, the present invention provides a method for detecting cancer characterized by the expression of the gene product of CEA and its homologues, comprising: (a) isolating a biological sample from a subject to identify the gene product and its homologues expressed by CEA in a human patient with cancer, wherein the sample contains the CEA gene product when the CEA gene is expressed; (b) utilizing the gene product as a biomarker by contacting the biological sample with an anti-CEA antibody or antibody fragment or composition thereof as described herein, such as ADx-CEA, to produce a sample-antibody complex; (c) removing any unbound antibodies, and then contacting the sample-antibody complex with a label specific to the antibody or the sample-antibody complex; and (d) detecting the presence of an antigen-antibody complex by detecting the label, wherein the detection of the label indicates the detection of cancer.

[0045] In some embodiments, the present invention provides a method for determining the state of cells in a sample, comprising: (a) obtaining the sample from a subject; contacting the sample with an antibody or antibody fragment described herein, such as ADx-CEA, or a composition thereof; and (c) determining the amount of CEA detected by the antibody or antibody fragment.

[0046] In some embodiments, the present invention provides a method for detecting pancreatic cancer in a patient, comprising: (a) taking a sample of the pancreas or blood from a patient suspected of having or having pancreatic cancer; (b) contacting the sample with an antibody or antibody fragment or composition thereof as described herein to form an antigen-antibody complex in the sample; (c) labeling the sample with a label specific to the antibody or antigen-antibody complex; (d) detecting the presence of the antigen-antibody complex by detecting the label; and (e) determining the CEA antigen level in comparison to a negative control, wherein a CEA antigen level higher than that of the negative control indicates pancreatic cancer. In some embodiments, the method is performed in vitro. In further embodiments, the pancreatic cancer is in an early stage, and the method can detect the CEA antigen in this early stage. In further embodiments, the pancreatic cancer is in stage I, II, IIA, or IIB, and the method can detect the CEA antigen in this early stage. In some embodiments, the pancreatic cancer is in stage II, IIA, or IIB.

[0047] In some embodiments, the present invention provides a kit for cancer detection comprising: (a) an antibody or antibody fragment having heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 1, 2, and 3, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 4, 5, and 6, respectively; and (b) a secondary antibody conjugated to a detectable label or a separate unconjugated detectable label, wherein the detectable label or the separate unconjugated detectable label binds to the secondary antibody, an antibody-antigen complex, or the monoclonal antibody of (a). In some embodiments, the kit is for the immunohistochemical detection of pancreatic cancer.

[0048] In some embodiments, the present invention provides an immunohistochemical method for detecting cancer in a tissue sample taken from a patient, comprising: (a) obtaining a tissue sample; (b) contacting the tissue sample with an antibody of an antibody fragment described herein, or a composition thereof; (c) after step (b), contacting the tissue sample with a secondary antibody, an antibody-antigen complex, or a detectable label that binds to an antibody; and (d) staining the tissue sample with immunohistochemical staining, wherein the staining indicates antibody binding and the presence of cancer in the tissue sample. In some embodiments, the cancer is pancreatic cancer.

[0049] In some embodiments, a composition is provided comprising a tissue, cell, or blood sample, an antibody or antibody fragment or composition thereof as described in the specification, and an antibody-antigen complex with a CEA antigen in the tissue, cell, or blood sample, wherein the sample is from a patient with cancer. In certain embodiments, the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer.

[0050] In some embodiments, the use of antibodies or antibody fragments or compositions thereof described herein for detecting cancer is provided. In further embodiments, the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer.

[0051] In some embodiments, a method for monitoring cancer progression and / or the therapeutic efficacy of an anticancer drug comprises: (a) obtaining an initial sample from a human patient having cancer at a first time point; (b) contacting the sample with an antibody or antibody fragment or composition thereof as described herein to form an antigen-antibody complex; (c) labeling the sample with a label specific to the antigen-antibody complex; (d) detecting the presence of the antigen-antibody complex by detecting the label; and (e) determining the level of CEA antigen detected by the antibody or antibody fragment to determine the CEA antigen associated with the patient's cancer. A method is provided that includes: (f) determining a baseline level; (g) obtaining a second sample at a second (later) time point, optionally, the second time point being after the period the subject is receiving therapy; (h) repeating steps (b) to (e) to determine a second CEA antigen level associated with the patient's cancer; and (h) determining that the patient's cancer has progressed if the CEA antigen level at the second time point is higher than the baseline level, and that the patient's cancer has regressed if the CEA antigen level at the second time point is lower than the baseline level. In some embodiments, the cancer is colorectal cancer, liver cancer, gastric cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. In some embodiments, the solid tumor cancer is pancreatic cancer. In some embodiments, an increase in CEA at the second time point indicates cancer progression. In some embodiments, a decrease in CEA at the second time point indicates cancer regression. In some embodiments, the first time point is before therapy or at the time of initial diagnosis. In some embodiments, the first time point is after therapy or at the time of initial diagnosis. In some embodiments, the second time point is after therapy has been received. In some embodiments, the method is performed in vitro. In some embodiments, the therapy is surgery including whippl treatment, distal pancreatectomy, and total pancreatectomy, radiotherapy, proton therapy, stereotactic radiotherapy (SBRT) or CyberKnife, immunotherapy, targeted therapy, and chemotherapy.

[0052] B. Glycosylated variants In certain embodiments, the antibodies provided herein are modified to increase or decrease the degree to which the antibody is glycosylated. The addition or deletion of glycosylation sites to an antibody can be conveniently achieved by modifying the amino acid sequence so that one or more glycosylation sites are created or removed.

[0053] If the antibody contains an Fc region, the carbohydrate bound to it may be modified. Natural antibodies produced by mammalian cells typically contain branched oligosaccharides, commonly bound by N-linking of the CH2 domain of the Fc region to Asn297. See, for example, Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose bound to GlcNAc in the "stem" of the branched oligosaccharide structure. In some embodiments, modification of the oligosaccharide in the antibody of the present invention may be performed to produce antibody variants having certain improved properties.

[0054] In some embodiments, antibody variants are provided having carbohydrate structures lacking fucose (directly or indirectly) bound to the Fc region. For example, the amount of fucose in such antibodies may be 1%–80%, 1%–65%, 5%–65%, or 20%–40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 by comparing it to the sum of all sugar structures (e.g., complex, hybrid, and high-mannose structures) bound to Asn297, as measured by MALDI-TOF mass spectrometry, as described in WO2008 / 077546. "Asn297" refers to the asparagine residue located at approximately position 297 (Eu numbering of Fc region residues) within the Fc region. However, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in the antibody. Such fucosylated variants may possess improved ADCC function. See, for example, U.S. Patent Publication No. 2003 / 0157108 (Presta, L.) and U.S. 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include U.S. 2003 / 0157108, U.S. 2000 / 61739, U.S. 2001 / 29246, U.S. 2003 / 0115614, U.S. 2002 / 0164328, U.S. 2004 / 0093621, and U.S. 2004 / 01321. References include 40, US2004 / 0110704, US2004 / 0110282, US2004 / 0109865, WO2003 / 085119, WO2003 / 084570, WO2005 / 035586, WO2005 / 035778, WO2005 / 053742, WO2002 / 031140, Okazaki et al. J.Mol.Biol.336:1239-1249(2004), and Yamane-Ohnuki et al. Biotech.Bioeng.87:614(2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells lacking protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986), US Patent Application No. 2003 / 0157108 A1 (Presta, L), and WO2004 / 056312 A1 (Adams et al., particularly in Example 11)), as well as knockout cell lines such as those containing the alpha-1,6-fucosyltransferase gene, FUT8, and knockout CHO cells (e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87:614 (2004), Kanda, Y. et al.) See also al., Biotechnol. Bioeng., 94(4):680-688(2006) and WO2003 / 085107).

[0055] Antibody variants are also provided with bifid oligosaccharides, for example, a bifid oligosaccharide bound to the Fc region of the antibody, which is bifid by GlcNAc. Such antibody variants may have reduced fucosylation function and / or improved ADCC function. Examples of such antibody variants include, for example, WO2003 / 011878 (Jean-Mairet et al.), U.S. Patent No. 6,602,684 (Umana et al.), and U.S.2005 / 0123546 (Umana et al.). Antibody variants having at least one galactose residue in the oligosaccharide bound to the Fc region are also provided. Such antibody variants may have improved CDC function. For examples of such antibody variants, please refer to WO1997 / 30087 (Patel et al.), WO1998 / 58964 (Raju, S.), and WO1999 / 22764 (Raju, S.).

[0056] C.Fc region variant In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of the antibody provided herein to generate an Fc region variant. The Fc region variant may include a human Fc region sequence (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc region) that includes amino acid modifications (e.g., substitutions) at one or more amino acid positions.

[0057] In certain embodiments, the present invention aims to provide antibody variants that possess some, but not all, effector functions, which are desirable candidates for applications where the in vivo half-life of the antibody is important, but certain effector functions (such as complement and ADCC) are unnecessary or harmful. In vitro and / or in vivo cytotoxic assays can be performed to confirm reduced / depleted CDC and / or ADCC activity. For example, an Fc receptor (FcR) binding assay can be performed to confirm that the antibody lacks FcgR binding (and therefore is likely to lack ADCC activity) but retains FcRn binding ability. NK cells, which are primary cells for mediating ADCC, express only FcgRIII, while monocytes express FcgRI, FcgRII, and FcgRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays for evaluating the ADCC activity of the target molecule are described in U.S. Patent No. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985), and No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be used (for example, for flow cytometry, see ACTI® non-radioactive cytotoxicity assay (CellTechnology, Inc., Mountain View, CA) and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells.Alternatively or additionally, the ADCC activity of the molecule of interest may be evaluated in vivo in animal models, such as those disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). A C1q binding assay can also be performed to confirm that the antibody is unable to bind C1q and therefore lacks CDC activity. See, for example, the C1q and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. To evaluate complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J.Immunol.Methods 202:163 (1996), Cragg, MS et al. Blood 101:1045-1052 (2003), and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance / half-life determination can also be performed using methods known in the art (see, for example, Petkova, S B et al., Int'l.Immunol. 18(12):1759-1769 (2006)).

[0058] Antibodies with reduced effector function include those having one or more substitutions among the Fc region residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Patent No. 6,737,056). Such Fc variants include the so-called "DANA" Fc variant, which involves substitutions of alanine residues 265 and 297, as well as Fc variants with two or more substitutions among the amino acids at positions 265, 269, 270, 297, and 327 (U.S. Patent No. 7,332,581).

[0059] Certain antibody variants exhibiting improved or reduced binding to FcR are described. (See, for example, U.S. Patent No. 6,737,056, WO2004 / 056312, and Shields et al., J. Biol. Chem. 9(2):6591-6604(2001).)

[0060] In certain embodiments, the antibody variant includes an Fc region having one or more amino acid substitutions that improve ADCC, for example, substitutions at positions 298, 333, and / or 334 of the Fc region (residue EU numbering).

[0061] In some embodiments, modifications resulting in alterations (i.e., either improvement or reduction) of C1q binding and / or complement-dependent cytotoxicity (CDC) are made in the Fc region, as described, for example, in U.S. Patent No. 6,194,551, WO99 / 51642, and Idusogie et al. J. Immunol. 164:4178-4184 (2000).

[0062] Antibodies exhibiting increased half-life and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J.Immunol. 117:587 (1976) and Kim et al., J.Immunol. 24:249 (1994)) are described in US2005 / 0014934A1 (Hinton et al.). These antibodies contain an Fc region with one or more substitutions that improve binding to FcRn in the Fc region. Examples of such Fc variants include substitutions in one or more of the Fc region residues: 238, 252, 254, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434, for example, substitutions in the Fc region residue 434 (e.g., U.S. Patent No. 7,371,826).

[0063] See also Duncan & Winter, Nature 322:738-40 (1988), U.S. Patent Nos. 5,648,260, 5,624,821, and WO94 / 29351 for other examples of Fc region variants.

[0064] In some embodiments, the antibody is provided according to a sequence listing, and its isotype is human IgG1. In some embodiments, the antibody is provided according to a sequence listing, and its isotype is human IgG2. In some embodiments, the antibody is provided according to a sequence listing, and its isotype is human IgG3. In some embodiments, the antibody is provided according to a sequence listing, and its isotype is human IgG4. [Table 1-1] [Table 1-2]

[0065] D. Cysteine-modified antibody variant In certain embodiments, it may be desirable to produce cysteine-modified antibodies, such as "thioM antibodies (thioMantibodies)," in which one or more residues of the antibody are substituted with cysteine ​​residues. In certain embodiments, the substituted residues occur in the accessible sites of the antibody. By substituting these residues with cysteine, the reactive thiol group is thereby positioned in the accessible sites of the antibody and can be used to produce an immunoconjugate by conjugating the antibody to a drug moiety or other moiety, such as a linker-drug moiety, as further described herein. In certain embodiments, one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain, A118 (EU numbering) of the heavy chain, and S400 (EU numbering) of the heavy chain Fc region. Cysteine-modified antibodies can be produced, for example, as described in U.S. Patent No. 7,521,541.

[0066] E. Antibody derivatives In certain embodiments, the antibodies provided herein may be further modified to include additional non-proteinoid moieties known and readily available in the art. Moieties suitable for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propropylene glycol homopolymers, prolipropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in production due to its stability in water. The polymers may have any molecular weight and may be branched or unbranched. The number of polymers bound to the antibody may vary, and if two or more polymers are bound, they may be the same molecule or different molecules. In general, the number and / or type of polymers used in derivatization is not limited but may be determined based on considerations such as the specific properties or functions of the antibody being improved, and whether the antibody derivative will be used for therapeutic purposes under specified conditions.

[0067] In other embodiments, an antibody-nonproteinate conjugate is provided that can be selectively heated by exposure to radiation. In some embodiments, the nonproteinate portion is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102:11600-11605 (2005)). The radiation may be of any wavelength that does not harm normal cells, but includes, but is not limited to, wavelengths that heat the nonproteinate portion to a temperature that kills cells adjacent to the antibody-nonproteinate portion.

[0068] F. Recombination Method Antibodies may be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567. In some embodiments, isolated nucleic acids encoding the anti-CEA antibody described herein are provided. Such nucleic acids may encode an amino acid sequence including the VL of the antibody and / or an amino acid sequence including the VH of the antibody (e.g., the light chain and / or heavy chain of the antibody). In further embodiments, one or more vectors (e.g., expression vectors) containing such nucleic acids are provided. In further embodiments, host cells containing such nucleic acids are provided. In one such embodiment, the host cell comprises (1) a vector comprising nucleic acids encoding an amino acid sequence including the VL of the antibody and an amino acid sequence including the VH of the antibody, or (2) a first vector comprising nucleic acids encoding an amino acid sequence including the VL of the antibody and a second vector comprising nucleic acids encoding an amino acid sequence including the VH of the antibody (e.g., transformed therein). In some embodiments, the host cell is a eukaryote, for example, a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., Y0, NS0, Sp20 cells). In some embodiments, a method is provided for producing an anti-CEA antibody, comprising culturing host cells containing nucleic acids encoding the antibody under conditions suitable for antibody expression, as provided above, and optionally recovering the antibody from the host cells (or host cell culture medium).

[0069] For recombinant production of anti-CEA antibodies, for example, nucleic acids encoding the antibodies described above are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids can be readily isolated and sequenced using conventional procedures (for example, by using oligonucleotide probes that can specifically bind to the genes encoding the heavy and light chains of the antibody).

[0070] Suitable host cells for cloning or expressing antibody-coding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, especially when glycosylation and Fc effector function are not required. For the expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Patents 5,648,237, 5,789,199, and 5,840,523. (Also see Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in E. coli.) After expression, antibodies can be isolated from bacterial cell paste in a soluble fraction and further purified.

[0071] In addition to prokaryotes, eukaryotes such as filamentous fungi or yeasts have "humanized" glycosylation pathways and are suitable cloning or expression hosts for antibody-coding vectors, including fungal and yeast strains that produce antibodies with partially or completely human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004) and Li et al., Nat. Biotech. 24:210-215 (2006).

[0072] Host cells suitable for the expression of glycosylated antibodies also originate from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for the transfection of Spodoptera frugiperda cells.

[0073] Plant cell cultures can also be used as hosts. See, for example, U.S. Patents 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe PLANTIBODIES® technology for antibody production in transgenic plants).

[0074] Vertebrate cells may be used as hosts. For example, mammalian cell lines adapted for growth in suspension may be useful. Other examples of useful mammalian host cell lines include SV40-transformed monkey kidney CV1 cell line (COS-7), human embryonic kidney cell line (e.g., 293 or 293 cells described in Graham et al., J. Gen Virol 36:59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical cancer cells (HELA), canine kidney cells (MDCK), buffalo rat hepatocytes (BRL 3A), human lung cells (W138), human hepatocytes (Hep G2), mouse mammary tumor cells (MMT 060562), e.g., Mather et al., Annnals These include TRI cells, MRC 5 cells, and FS4 cells, as described in NYAcad.Sci.383:44-68(1982). Other useful mammalian host cell lines include DHFR - Examples include Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), as well as myeloma cell lines such as Y0, NS0, and Sp2 / 0. For an overview of specific mammalian host cell lines suitable for antibody production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0075] G. Immunoconjugates The present invention also provides an immunoconjugate comprising the anti-CEA antibody herein conjugated to one or more other therapeutic agents or radioisotopes.

[0076] In another embodiment, the immunoconjugate comprises the antibody described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioconjugates. Examples include At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , and radioisotopes of Lu. When the radioconjugate is used for detection, the radioconjugate may comprise, for example, a radioactive atom for scintigraphic studies of tc99m or I123, or a spin label for nuclear magnetic resonance (NMR) imaging (also referred to as magnetic resonance imaging, MRI) such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

[0077] Antibody conjugates can be prepared using various bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), difunctional derivatives of imide esters (e.g., dimethylHCl adipiimidoate), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bis-azide compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene-2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, lysine immunotoxins can be prepared as described in Vitetta et al., Science 238:1098 (1987). For example, carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for the conjugation of radioactive nucleotides to antibodies. See WO94 / 11026. The linker may be a “cleavable linker” that facilitates the release of cytotoxic drugs in cells. For example, acid-unstable linkers, peptidase-sensitive linkers, photosensitive linkers, dimethyl linkers, or disulfide-containing linkers may be used (see Chari et al., Cancer Res. 52:127-131 (1992), U.S. Patent No. 5,208,020).

[0078] The immunoconjugates or ADCs used herein expressly intend to be such conjugates prepared with crosslinking reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, as well as commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL, USA) SVSB (succinimidyl-(4-vinylsulfone)benzoate).

[0079] H. Pharmaceutical preparations and compositions The pharmaceutical formulations or compositions of anti-CEA antibodies described herein are prepared by mixing an antibody of desired purity, in the form of a lyophilized formulation or aqueous solution, with one or more optional pharmaceutically acceptable carriers, diluents, and / or excipients (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). The pharmaceutically acceptable carriers, diluents, and excipients are generally non-toxic to the recipient at the dosage and concentration used and include buffers such as sterile water, phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; parabens and alkyls such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); and low molecular weight (less than about 10 residues) polypeptides. This includes, but is not limited to, butylates; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, algin, or lysine; monosaccharides, disaccharides, and other carbohydrates, such as glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; counterions that form salts, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers as used herein include interstitial drug dispersants such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), such as human soluble PH-20 hyaluronidase glycoproteins like rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs containing rHuPH20 and methods of use are described in U.S. Patent Publications 2005 / 0260186 and 2006 / 0104968.In one embodiment, sHASEGP is combined with one or more additional glycosaminoglycans, such as chondroitinase.

[0080] An example of a lyophilized antibody preparation is described in U.S. Patent No. 6,267,958. Examples of aqueous antibody preparations are described in U.S. Patent No. 6,171,586 and WO2006 / 044908, the latter of which is histidine acetate buffer.

[0081] The formulations or compositions described herein may also contain two or more active ingredients necessary for the specific indication being treated, preferably having complementary activities that do not adversely affect each other. Such active ingredients are preferably present in combination in amounts effective for the intended purpose.

[0082] The active ingredient may be encapsulated, for example, in microcapsules prepared by droplet formation technology or interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0083] A sustained-release preparation may be prepared. A suitable example of a sustained-release preparation is a translucent matrix of a solid hydrophobic polymer containing an antibody, the matrix being in the form of a molded article, such as a film or microcapsules.

[0084] Preparations or compositions used for in vivo administration are generally sterile. Sterility can be easily achieved, for example, by filtration through a sterile filtration membrane.

[0085] I. Implementation The following embodiments are provided. Embodiment 1. An isolated antibody or antibody fragment comprising (a) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, (c) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, (d) LCDR1 containing the amino acid sequence of SEQ ID NO: 4, (e) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (f) LCDR3 containing the amino acid sequence of SEQ ID NO: 6. Embodiment 2. The antibody has a heavy chain variable region (V H ) and light chain variable region (V L ) including, V H However, the amino acid sequence of sequence number 7 is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and V L The isolated antibody of Embodiment 1, wherein the amino acid sequence is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to that of SEQ ID NO: 8. Embodiment 3. The antibody has a heavy chain variable region (V H ) and light chain variable region (V L ) including, V H However, it contains the amino acid sequence of SEQ ID NO: 7, V L However, the isolated antibody of Embodiment 1 or 2 contains the amino acid sequence of SEQ ID NO: 8. Embodiment 4. An isolated antibody or antibody fragment comprising (a) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, (c) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, (d) LCDR1 containing the amino acid sequence of SEQ ID NO: 4, (e) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (f) LCDR3 containing the amino acid sequence of SEQ ID NO: 6, and a heavy chain variable region (V H ) and light chain variable region (V L ) including, V H However, the amino acid sequence of sequence number 7 is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and V LAn isolated antibody or antibody fragment that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8. Embodiment 5. An isolated antibody or antibody fragment from any one of the prior embodiments, wherein the antibody is a monoclonal antibody. Embodiment 6. An isolated antibody or antibody fragment from any one of the prior embodiments, wherein the antibody is a fully human antibody. Embodiment 7. An isolated antibody or antibody fragment from any one of the prior embodiments, wherein the antibody is an antibody fragment. Embodiment 8. The isolated antibody or antibody fragment of Embodiment 7, wherein the fragment is Fab, Fab', Fv, scFv, or (Fab')2. Embodiment 9. An isolated antibody or antibody fragment from any one of Embodiments 1 to 5, wherein the antibody is a full-length antibody. Embodiment 10. An isolated antibody or antibody fragment from any one of Embodiments 1 to 9, wherein the antibody Fc region, if present, includes IgG1, IgG2, IgG3, IgG4, IgG4.1, or IgG4.2. Embodiment 11. A composition comprising one antibody or antibody fragment from any one of Embodiments 1 to 10 and a pharmaceutically acceptable carrier. Embodiment 12. An isolated antibody or antibody fragment from any one of Embodiments 1 to 10, immobilized on a solid phase. Embodiment 13. A detectably labeled isolated antibody or antibody fragment from any one of Embodiments 1 to 10. Embodiment 14. An isolated antibody or antibody fragment from any one of Embodiments 1 to 10, conjugated to a cytotoxic radionuclide. Embodiment 15. An isolated antibody or antibody fragment from any one of Embodiments 1 to 10, conjugated with a cytotoxic drug. Embodiment 16. An isolated antibody or antibody fragment from any one of Embodiments 1 to 10, conjugated to a cytotoxic protein. Embodiment 17. An isolated DNA sequence encoding one of the antibodies or antibody fragments from Embodiments 1 to 10. Embodiment 18. DNA of Embodiment 17, comprising SEQ ID NO: 11 or a fragment thereof, or a sequence that is at least 80, 90, or 95% identical to SEQ ID NO: 11. Embodiment 19. DNA of Embodiment 17, comprising SEQ ID NO: 12 or a fragment thereof, or a sequence that is at least 80, 90, or 95% identical to SEQ ID NO: 12. Embodiment 20. DNA of Embodiment 17, comprising SEQ ID NO: 11 or a fragment thereof and SEQ ID NO: 12 or a fragment thereof, or comprising a sequence that is at least 80, 90, or 95% identical to SEQ ID NO: 11 and a sequence that is at least 80, 90, or 95% identical to SEQ ID NO: 12. Embodiment 21. A vector comprising any one of the DNA sequences from Embodiments 17 to 20. Embodiment 22. Host cells transformed with the vector of Embodiment 21. Embodiment 23. A process for antibody production, comprising culturing the host cells of Embodiment 22 and isolating antibody molecules. Embodiment 24. A V molecule whose amino acid sequence is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to that of SEQ ID NO: 7. H And V is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8. L Isolated antibodies containing [the specified substance]. Embodiment 25. A method for treating cancer, comprising administering a therapeutically effective amount of an anti-CEA antibody according to any one of claims 1 to 10 or 14 to 16, the composition according to claim 11, or DNA or a vector according to any one of claims 17 to 21 to a subject in need thereof. Embodiment 26. An immunoassay for detecting a CEA antigen, comprising: (a) contacting the sample with one antibody or antibody fragment from Embodiments 1 to 10 in an effective binding amount; and (b) detecting the binding of the antibody to the CEA antigen. Embodiment 27. The immunoassay of Embodiment 26, wherein the assay is used to detect cancer cells expressing the CEA antigen. Embodiment 28. The immunoassay of Embodiment 26, wherein the assay is used to detect solid tumors. Embodiment 29. The immunoassay of Embodiment 27 or 28, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. Embodiment 30. A method for detecting cancer in a subject, comprising contacting a sample isolated from a subject having cancer or a subject suspected of having cancer with one antibody from Embodiments 1 to 10. Embodiment 31. The method of Embodiment 30, wherein the cancer is a solid tumor. Embodiment 32. The method of Embodiment 30, wherein the solid tumor is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. Embodiment 33. A kit for immunohistochemical detection of solid tumors containing cells expressing a CEA antigen, comprising: (a) an antibody described in any one of Embodiments 1 to 10; and (b) a secondary antibody conjugated to a detectable label, which, when bound to a CEA antigen, binds to the antibody in (a) and can be detected. Embodiment 34. A method for determining the state of a solid tumor in a subject, comprising: (a) taking a sample from a subject having a solid tumor; (b) contacting the sample with one antibody or antibody fragment from Embodiments 1 to 10 to form a complex of CEA antigen and antibody or antibody fragment; (c) labeling the sample with a label specific to the antigen-antibody complex; and (d) detecting the presence of the antigen-antibody complex by detecting the label. Embodiment 35. The method of Embodiment 34, wherein the solid tumor cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. Embodiment 36. The method of Embodiment 34, wherein the solid tumor cancer is pancreatic cancer. Embodiment 37. Any one of Embodiments 34 to 36, wherein the subject has been diagnosed with cancer and is receiving or planning to receive therapy. Embodiment 38. The method of Embodiment 37, wherein the sample is isolated from the subject before the start of therapy. Embodiment 39. The method of Embodiment 37, wherein the sample is isolated from the subject after the start of therapy. Embodiment 40. Any one of Embodiments 34 to 39, further comprising repeating steps (a) to (d) at a later point in time. Embodiment 41. The method of Embodiment 40, wherein the later time point is after the subject has started therapy. Embodiment 42. The method of Embodiment 40, wherein the later point in time is after the subject has initiated a new or second (co)therapy. Embodiment 43. The method of Embodiment 41 or 42, wherein the therapy is chemotherapy or radiation. Embodiment 44. The method according to claim 43, wherein the chemotherapy is erlotinib, fluorouracil, or oxaliplatin. Embodiment 45. The method according to claim 41 or 42, wherein the therapy is surgery including Whipple procedure, distal pancreatectomy and total pancreatectomy, radiotherapy, proton therapy, stereotactic radiotherapy (SBRT) or CyberKnife, immunotherapy, targeted therapy, or chemotherapy. Embodiment 46. Any one of Embodiments 34 to 45, wherein the detected CEA antigen level is determined, with a higher CEA level at a later time point indicating that the therapy is fully effective, and the same or lower CEA antigen level at a later time point indicating that the therapy is at least partially effective. Embodiment 47. Any one of Embodiments 34 to 46, wherein the subject is in a state of remission. Embodiment 48. The method of Embodiment 47, further comprising repeating steps (a) to (d) at a point after the subject has entered remission, wherein the CEA level is determined, and a higher CEA level at a later point indicates that the cancer is no longer in remission, and the same or lower CEA level at a later point indicates that the therapy is continuing to be in remission. Embodiment 49. Any one of Embodiments 34 to 48, wherein the sample is blood, tissue, or cells, including whole blood, serum, or plasma. Embodiment 50. Any one of Embodiments 34 to 49, wherein the method is an alternative to computed tomography. Embodiment 51. A method for detecting cancer characterized by the expression of the gene product of CEA and its homologues, comprising: (a) identifying the gene product and its homologues expressed by CEA in a human patient with cancer by isolating a biological sample from a subject, wherein the sample contains the CEA gene product when the CEA gene is expressed; (b) utilizing the gene product as a biomarker by contacting the biological sample with an anti-CEA antibody according to any one of claims 1 to 10 or 14 to 16, or the composition according to claim 11, to produce a sample-antibody complex; (c) removing any unbound antibodies, and then contacting the sample-antibody complex with a label specific to the antibody or the sample-antibody complex; and (d) detecting the presence of an antigen-antibody complex by detecting the label, wherein the detection of the label indicates the detection of cancer. Embodiment 52. A method for determining the state of cells in a sample, a. Obtaining the sample from the subject, b. Contacting the sample with one of the antibodies or antibody fragments from Embodiments 1 to 10 or 14 to 16, or the composition of Embodiment 11, c. A method comprising determining the amount of CEA detected by an antibody or antibody fragment. Embodiment 53. A method for detecting pancreatic cancer in a patient, comprising: (a) taking a sample of the pancreas or blood from a patient suspected of having pancreatic cancer or having pancreatic cancer; (b) contacting the sample with one antibody or antibody fragment from Embodiments 1 to 10 or 14 to 16, or the composition described in claim 11, thereby forming an antigen-antibody complex in the sample; (c) labeling the sample with a label specific to the antibody or antigen-antibody complex; (d) detecting the presence of the antigen-antibody complex by detecting the label; and (e) determining the CEA antigen level in comparison with a negative control, wherein a CEA antigen level higher than that of the negative control indicates pancreatic cancer. Embodiment 54. The method of Embodiment 53, wherein the method is performed in vitro. Embodiment 55. The method of Embodiment 53 or 54, wherein pancreatic cancer is in an early stage, and the method can detect the CEA antigen in this early stage. Embodiment 56. The method according to any one of Embodiments 53 to 55, wherein the pancreatic cancer is stage I, II, III, or IV, and the method can detect the CEA antigen in this early stage. Embodiment 57. A kit for immunohistochemical detection of pancreatic cancer, comprising: (a) a monoclonal antibody having heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs. 1, 2, and 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs. 4, 5, and 6, respectively; and (b) a secondary antibody conjugated to a detectable label or a separate unconjugated detectable label, wherein the detectable label or the separate unconjugated detectable label binds to the secondary antibody, an antibody-antigen complex, or the monoclonal antibody of (a). Embodiment 58. An immunohistochemical method for detecting pancreatic cancer in a tissue sample taken from a patient, comprising: (a) obtaining a tissue sample; (b) contacting the tissue sample with an antibody of any one antibody fragment from Embodiments 10 or 14 to 16, or the composition described in claim 11; (c) after step b), contacting the tissue sample with a secondary antibody, an antibody-antigen complex, or a detectable label that binds to an antibody; and (d) staining the tissue sample with immunohistochemical staining, wherein the staining indicates antibody binding and the presence of pancreatic cancer in the tissue sample. Embodiment 59. A composition comprising a tissue sample and an antibody-antigen complex of any one of Embodiments 10 or 14 to 16, or the composition described in claim 11, wherein the tissue sample is from a patient suffering from cancer. Embodiment 60. The composition of Embodiment 59, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. Embodiment 61. Use of the composition of Embodiment 11, or any one antibody or antibody fragment from Embodiments 1-10 or 11-14, for detecting cancer. Embodiment 62. The composition of Embodiment 61, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. Embodiment 63. A method for monitoring the progression of cancer and / or the therapeutic efficacy of a cancer drug, comprising: obtaining an initial sample from a human patient having cancer at a first time point; contacting the sample with one antibody or antibody fragment from any one of Embodiments ~10 or 14~16, or the composition described in claim 11, to form an antigen-antibody complex; labeling the sample with a label specific to the antigen-antibody complex; detecting the presence of the antigen-antibody complex by detecting the label; and determining the CEA antigen level detected by the antibody or antibody fragment to determine the patient's cancer and A method comprising: determining a baseline level of relevant CEA antigen; obtaining a second sample at a second (later) time point, optionally, the second time point being after the period during which the subject is receiving therapy; repeating steps (b) to (e) to determine a second CEA antigen level related to the patient's cancer; determining that the patient's cancer has progressed if the CEA antigen level at the second time point is higher than the baseline level, and determining that the patient's cancer has regressed if the CEA antigen level at the second time point is lower than the baseline level. Embodiment 64. The method of Embodiment 63, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. Embodiment 65. The method of Embodiment 63, wherein the solid tumor cancer is pancreatic cancer. Embodiment 66. The method of Embodiment 63, wherein an increase in CEA at a second time point indicates cancer progression. Embodiment 67. The method of Embodiment 63, wherein the decrease in CEA at a second time point indicates cancer regression. Embodiment 68. The method of Embodiment 63, wherein the first time point is before therapy or at the time of initial diagnosis. Embodiment 69. The method according to Embodiment 63, wherein the first time point is after therapy or at the time of initial diagnosis. Embodiment 70. The method of Embodiment 63, wherein the second time point is after the therapy has been received. Embodiment 71. The method of Embodiment 63, wherein the method is performed in vitro. Embodiment 72. The method of Embodiment 69, wherein the therapy is surgery including whipple treatment, distal pancreatectomy, and total pancreatectomy, radiotherapy, proton therapy, stereotactic radiotherapy (SBRT) or CyberKnife, immunotherapy, targeted therapy, and chemotherapy. [Examples]

[0086] Example 1. Antibodies were prepared using natural (wt) CEA antigen as an immunogen, producing approximately 19,200 hybridomas for screening. Approximately 20 promising candidates were further evaluated, and ultimately five clones were selected for follow-up, as follows. After determining the IgG isotype (IgG1, G2, G2a, G2b) of the hybridoma clones, the hybridoma cell line cultures (2 × 10⁶) were extracted using an RNA extraction kit (e.g., Qiagen Mini RNeasy kit) according to the kit instructions. 6Total RNA was extracted from the sample. The RNA was reverse transcribed into complementary DNA (cDNA) using the SuperScript® III first strand synthesis system (ThermoFisher Scientific, Carlsbad, CA, USA). 1 μg of cDNA from each sample was subjected to polymerase chain reaction (PCR). The V region of the cDNA sample from the hybridoma clone (ADx-CEA) was amplified using mouse universal Ig heavy or light chain primers. The universal primers were designed from highly conserved regions as described in Dattamajumdar, Anupam K., et al. "Rapid cloning of any rearranged mouse immunoglobulin variable genes." Immunogenetics 43.3 (1996):141-151. Gene H was amplified using primers HF and HR, and gene K was amplified using primers KF and KR. See Table 2. The heavy chain primer sequences were as follows: VH 5'-tgaggtgcagctggaggagtc-3' (SEQ ID NO: 13) and JH 5'-gtgaccgtggtcccttggccccag-3' (SEQ ID NO: 14). The light chain primer sequences were as follows: VK 5'-gacattctgatgacccagtct-3' (SEQ ID NO: 15) and JK 5'-ttttatttccagcttggtccc-3' (SEQ ID NO: 16). The pairs are listed in Table 2 below. PCR cycles were performed for the first 6 cycles at 94°C for 15 seconds, 62°C (-1.2°C / cycle) for 30 seconds, and 72°C for 30 seconds, followed by 30 cycles at 94°C for 15 seconds, 56°C for 30 seconds, and 72°C for 30 seconds. One hybridoma was selected as a lead for subsequent studies, and this hybridoma produced the antibody ADx-CEA, having the CDRs of SEQ ID NOs. 1-6, the VH of SEQ ID NO. 7, the VL of SEQ ID NO. 8, the full heavy chain of SEQ ID NO. 9, and the full light chain of SEQ ID NO. 10, as described herein. Throughout, this lead antibody is referred to as ADx-CEA. The amplicon of ADx-CEA is shown in Figure 1, with the heavy and light chains running on 1% agarose at approximately 380-500 bp. [Table 2-1] [Table 2-2]

[0087] Example 2. PCR products were purified and cloned into pCR4-TOPO vectors using the TA cloning strategy (ThermoFisher Scientific, Carlsbad, CA, USA) according to the manufacturer's instructions. Three to five single colonies were selected, and plasmid DNA was amplified using primers specific to the vector DNA sequence. Subcloning was performed as needed. Plasmids from each colony were isolated using the Miniprep Kit (Qiagen Inc). PCR inserts were validated by restriction analysis using EcoR1 digestion, and both strands were sequenced using M13 universal primers with cyclic sequencing using fluorescent dye terminators and capillary-based electrophoresis. DNA sequence data from all constructs were analyzed to determine the consensus sequences of the heavy and light strands. The consensus sequences were compared to all known variable region sequences to rule out artifacts and / or process contamination. The consensus sequences were then analyzed using online tools to verify that they were capable of encoding productive immunoglobulins. Sequence comparisons with mouse and human databases (GenBank) were performed using NCBI's (NIH, Bethesda, MD) BLAST (Basic Local Alignment Search Tool) against the Kabat database (to identify CDR1 and CDR2) and the IMGT / V Quest program (to detect CDR3), with the query being the DNA sequence of the ADx-CEA clone. Representative BLAST results for the heavy and light chains of ADx-CEA are shown in Figures 2 and 3. For validation purposes, and as shown in Figures 2 and 3, the reference genome sequences of IGHV4-4*02;IGHV3-33*08 and IGHV4-30-4*01 were found to be the most reliable (66-67%) sequences for detecting homology in the V region when blasted against Homo Sapiens Ig germline sequences. The most reliable variable (V) gene match was found to be IGHV4-4*02, and the most reliable diversity (D) gene match was found to be IGHD2-8*01.The most reliable matching of the conjugation (J) gene segment was found to be IGHJ6*02.

[0088] Example 3. A lead candidate monoclonal antibody, referred to herein as "ADx-CEA," was selected. Approximately 1 μg and 5 μg of purified ADx-CEA were suspended in PBS and applied to an SDS-PAGE gel under reducing conditions (boiled for 3 minutes in sample buffer containing beta-mercaptoethanol and 10% SDS), and to a 10% Bis-Tris gel (lanes 3, 5, 7, and 9, respectively) under non-reducing conditions. The gels were run at 129 volts and then stained with Coomassie Blue R350 (0.1 w / v), 20% v / v methanol, and 10% v / v acetic acid, and destained in water with 50% v / v methanol using 10% v / v acetic acid.

[0089] As shown in Figure 4, lane 3 contained 1 μg of reduced ADx-CEA mAb. Lane 5 contained 5 μg of reduced ADx-CEA mAb. Lane 7 contained 1 μg of unreduced ADx-CEA mAb. Lane 9 contained 5 μg of unreduced ADx-CEA mAb. Under denaturation conditions, the heavy chain of ADx-CEA (IgG1 kappa) was detected at approximately 50 kDa. The light chain of ADx-CEA was detected at approximately 25 kDa (Figure 4).

[0090] Example 4. 25 μl of sample buffer containing 50 μg of recombinant CEA (Mybiosource Carcinoembryonic Recombinant Protein, catalog number MBS142843) was boiled for 3 minutes and loaded onto a 4–12% Tris-Glycine gel with 5 μl of molecular marker. The gel was run at 125 V for 1.5 hours. The gel was then transferred to a PVDF membrane. The membrane was incubated overnight at 4°C with ADx-CEA mAb. After rinsing the membrane with PBST, it was incubated with a secondary antibody (sheep anti-mouse IgG-HRP, diluted 1:1000 in PBST) for 1 hour and rinsed with PBST. Bands visualized in 1-Step NBT / BCIP solution.

[0091] Under reducing conditions, and according to the manufacturer's instructions, ADx-CEA detected two bands at molecular weights of 16 kDa and 25 kDa human CEA protein, as indicated by the arrows in Figure 5. Figure 5 represents a replicated experiment.

[0092] Example 5. PANC-1 cells (a human pancreatic cancer cell line isolated from ductal cell-derived pancreatic cancer; purchased from ATCC) were cultured for 18 hours on glass-bottomed wells. Cells were fixed with 10% paraformaldehyde and permeabilized with Triton® X-100. Cells were washed with PBS and incubated with ADx-CEA (5 μg / ml) for 15 minutes. Cells were washed with PBS again and incubated with FITC conjugate mouse IgG (4 μg / ml) for 15 minutes. Cells were washed and staining was visualized under an immunofluorescence microscope.

[0093] Figures 6A and 6B show representative images of indirect immunofluorescence staining of CEA detected by ADx-CEA, which is localized as punctate cells within vesicles. Figure 6A shows a phase-contrast image. Figure 6B shows an immunofluorescence stained image.

[0094] Example 6. Plasma samples from healthy donors (n=9) and patients (n=17) who were untreated and diagnosed with pancreatic cancer at various stages (IA, IB, IIA, IIB, III, IIIA, IV) were diluted with PBS. Sample buffer was added to a final volume of 25 μl and boiled for 3 minutes. The samples were loaded onto 4–12% Tris-Glycine gels with 5 μl of molecular markers. The gels were run at 125 V for 1.5 hours. The gels were then transferred to PVDF membranes. The membranes were incubated overnight at 4°C with ADx-CEA. After rinsing the membranes with PBST, they were incubated with a secondary antibody (sheep anti-mouse IgG-HRP, diluted 1:1000 in PBST) for 1 hour and rinsed with PBST. Bands visualized with 1-Step NBT / BCIP solution.

[0095] ADx-CEA detected CEA protein in plasma blood samples from healthy donors and patients diagnosed with pancreatic cancer. Figure 7. CEA protein expression showed varying levels, with low levels of CEA detected in healthy blood samples (n=9). Blood analysis of pancreatic cancer patients diagnosed at various stages showed that CEA protein levels increased with stage (n=17).

[0096] Example 7. Tissue array slides (BiocoreUSA, catalog number BC001157) with formalin-fixed paraffin-embedded (FFPE) tissue sections were used. The slides were deparaffinized with xylene and hydrated with a series of alcohols. Antigen recovery was performed in a steamer in citrate-EDTA buffer (pH 6.0) for 20 minutes. The slides were treated with H2O2 for 10 minutes, and then with a Background Sniper (Biocare Medical, catalog number BS966) for 10 minutes. The primary antibody was diluted 1:50 in NDB Antibody Diluent Buffer for 60 minutes. Antibody staining detection was achieved using Biocare Mach 3 reagents, with 10 minutes incubation for each component. Counterstaining was performed using Gill's II Hematoxylin. The slides were then dehydrated with alcohol, cleared with xylene, and mounted on Permount. The presence of staining was determined using the Lab Vision IHC 360 Autostainer and the Dako Link plus IHC System.

[0097] ADx-CEA detected early-stage pancreatic cancer. Figure 8. As shown in Figure 8, the DAKO anti-human commercial CEA mAb showed false-negative staining in pancreatic cancer tissues of various stages that were partially positive, staining only stage II tissue, and not stages I, III, and IV. On the other hand, ADx-CEA showed positive staining in the same tissues, including stages I-IV tissue. The staining showed membrane, cytoplasmic, and patterned staining, indicating that the expression of detected CEA increased with increasing stage. Pathologists confirmed that the stained tissues were diagnosed as pancreatic cancer.

[0098] Example 8. Immunohistochemical (IHC) staining was performed using ADx-CEA in a total of 215 tissue samples, including healthy, normal human tissue (n=19) and patient tissues diagnosed with pancreatic cancer at various stages (n=196), and was compared in parallel using a commercially available FDA-approved mouse anti-human CEA antibody from DAKO.

[0099] The calculated susceptibility of ADx-CEA was 99.5%, while that of commercially available mAbs was 34%, as shown in Tables 3-5 and Figures 9A-B. Susceptibility and specificity for the early stages (I, II) are shown in Figures 10A-B. Susceptibility and specificity for the later stages (III, IV) are shown in Figures 11A-B. [Table 3]

[0100] Tables 4 and 5 show the frequency distribution and corresponding susceptibility and specificity. [Table 4]

[0101] ADx-CEA susceptibility (estimated using data from Table 4): 195 / 196 = 0.9948 × 100 = 99.5%

[0102] Specificity of ADx-CEA (estimated using data from Table 4): 19 / 19 = 1.00 × 100 = 100% [Table 5]

[0103] DAKO-CEA susceptibility (estimated using data from Table 5): 66 / 196 = 0.3367 × 100 = 34%

[0104] Specificity of DAKO-CEA (estimated using data from Table 5): 19 / 19 = 1.00 × 100 = 100%

[0105] Example 9. The human BxPC-3 pancreatic adenocarcinoma cell line was purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 (American Type Culture Collection, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Thermostat Scientific, Inc.) and maintained at 37°C in a 5% CO2 atmosphere.

[0106] Soft agar colony formation assay: BxPC-3 cells (2,000 cells) were suspended in ADx-CEA in 0.3% Noble agar (Difco; BD Biosciences, Franklin Lakes, NJ, USA) in RPMI-1640 supplemented with 10% FBS, or in PBS alone, and then placed on 0.8% Noble agar in 12-well tissue culture plates. Colonies were grown in growth medium for 2.5 weeks, colony formation was observed, and the colonies were counted for data analysis.

[0107] BxPC-3 cells were cultured in soft agar in the absence of ADx-CEA (PBS only) and in the presence of different concentrations of ADx-CEA. After 2.5 weeks, colonies were imaged using an inverted microscope (Figure 12A-B). The well images are representative of three independent experiments.

[0108] BxPC-3 cells were grown in soft agar in PBS or 10, 25, and 50 μg / mL ADx-CEA. After 2.5 weeks, individual colonies larger than 70 μm were counted. The experiment was repeated three times. The statistical significance of the difference in total colony count between the control and treated samples was determined by Student's t-test (*p<0.005) (Figure 12C). BxPC-3 cells showed a dose-dependent decrease in colony formation in the presence of 10 μg / mL, 25 μg / mL, and 50 μg / mL ADx-CEA.

[0109] Example 10. CEA protein expression was validated using IHC staining with ADx-CEA as described herein in healthy tissues from healthy individuals and cancer patients, as well as in healthy and cancerous tissues. The antibody was tested on tissues from the breast, lymph, cervix, prostate, pancreas, ovary, bladder, kidney, uterus, colon, liver, brain, rectum, esophagus, stomach, lung, and uterus. Cancerous tissues from the pancreas (Figure 13A), colon (Figure 13B), and liver (Figure 13C) showed positive membranocytoplasmic staining for CEA expression. Breast and kidney cancers showed weak staining (data not shown). Tissues from the lymph, cervix, prostate, ovary, esophagus, bladder, uterus, brain, stomach, lung, and rectum showed negative staining for CEA expression (data not shown). The present invention provides, for example, the following items: (Item 1) An isolated antibody or antibody fragment comprising (a) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (b) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, (c) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, (d) LCDR1 containing the amino acid sequence of SEQ ID NO: 4, (e) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (f) LCDR3 containing the amino acid sequence of SEQ ID NO: 6. (Item 2) An isolated antibody, wherein the antibody has a heavy chain variable region (V H ) and light chain variable region (V L ) including the V H However, the amino acid sequence of SEQ ID NO: 7 is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and contains HCDR3 including SEQ ID NO: 3, and the V L An isolated antibody containing LCDR3, which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8, and which also contains SEQ ID NO: 6. (Item 3) The antibody has a heavy chain variable region (V H ) and light chain variable region (V L ) including the V H However, it includes the amino acid sequences of SEQ ID NO: 7 and SEQ ID NO: 3, and the V L However, the isolated antibody described in item 1 or 2 contains the amino acid sequences of SEQ ID NO: 8 and SEQ ID NO: 6. (Item 4) The aforementioned antibody is a monoclonal antibody, or an isolated antibody or antibody fragment as described in any one of the preceding items. (Item 5) The aforementioned antibody is a fully human antibody, and is an isolated antibody or antibody fragment as described in any one of the preceding items. (Item 6) The aforementioned antibody is an antibody fragment, as described in any one of the preceding items, an isolated antibody or antibody fragment. (Item 7) The aforementioned fragment is Fab, Fab', Fv, scFv, or (Fab') 2 The isolated antibody or antibody fragment described in item 6. (Item 8) The aforementioned antibody is a full-length antibody, and is an isolated antibody or antibody fragment as described in any one of items 1 to 5. (Item 9) An isolated antibody or antibody fragment according to any one of items 1 to 8, wherein the Fc region of the antibody contains IgG1, IgG2, IgG3, IgG4, IgG4.1, or IgG4.2. (Item 10) A composition comprising an antibody or antibody fragment described in any one of items 1 to 9, and a pharmaceutically acceptable carrier. (Item 11) An isolated antibody or antibody fragment, immobilized on a solid phase, as described in any one of items 1 to 9. (Item 12) A detectably labeled isolated antibody or antibody fragment as described in any one of items 1 to 9. (Item 13) An isolated antibody or antibody fragment conjugated with a cytotoxic radionuclide, as described in any one of items 1 to 9. (Item 14) An isolated antibody or antibody fragment conjugated with a cytotoxic drug, as described in any one of items 1 to 9. (Item 15) An isolated antibody or antibody fragment conjugated to a cytotoxic protein, as described in any one of items 1 to 9. (Item 16) An isolated DNA sequence encoding an antibody or antibody fragment as described in any one of items 1 to 9. (Item 17) DNA as described in item 16, including sequence number 11 or a fragment thereof. (Item 18) DNA as described in item 16, including sequence number 12 or a fragment thereof. (Item 19) DNA as described in item 16, comprising SEQ ID NO: 11 or a fragment thereof, and SEQ ID NO: 12 or a fragment thereof. (Item 20) A vector containing the DNA sequence described in any one of items 16-19. (Item 21) Host cells transformed with the vector described in item 20. (Item 22) A process for antibody production, comprising culturing host cells as described in item 21 and isolating antibody molecules. (Item 23) The amino acid sequence of SEQ ID NO: 7 is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and contains SEQ ID NO: 3. H And, the amino acid sequence of SEQ ID NO: 8 is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and contains SEQ ID NO: 6. L Isolated antibodies containing [the specified substance]. (Item 24) A method for treating cancer, comprising administering to a subject in need an effective amount of an anti-CEA antibody described in any one of items 1 to 9 or 13 to 15, a composition described in item 10, or DNA or a vector described in any one of items 16 to 20. (Item 25) An immunoassay for detecting a CEA antigen, comprising: (a) contacting a sample with an antibody or antibody fragment described in any one of items 1 to 9 of the effective binding amount; and (b) detecting the antigen by detecting the binding of the antibody to the CEA antigen. (Item 26) The immunoassay described in item 25, wherein the assay is used to detect cancer cells expressing the CEA antigen. (Item 27) The immunoassay described in item 25, wherein the assay is used to detect solid tumors. (Item 28) The immunoassay described in item 26 or 27, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. (Item 29) A method for detecting cancer in a subject, comprising contacting a sample isolated from a subject having cancer or a subject suspected of having cancer with an antibody described in any one of items 1 to 9. (Item 30) The method according to item 29, wherein the cancer is a solid tumor. (Item 31) The method according to item 29, wherein the solid tumor is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. (Item 32) A kit for immunohistochemical detection of solid tumors containing cells expressing the CEA antigen, comprising: (a) an antibody as described in any one of items 1 to 9; and (b) a secondary antibody conjugated to a detectable label, which, when bound to the CEA antigen, binds to the antibody in (a) and can be detected. (Item 33) A method for determining the state of a solid tumor in a subject, comprising: (a) taking a sample from a subject having a solid tumor; (b) contacting the sample with an antibody or antibody fragment described in any one of items 1 to 9, thereby forming a complex between the CEA antigen and the antibody or antibody fragment; (c) labeling the sample with a label specific to the antigen-antibody complex; and (d) detecting the presence of the antigen-antibody complex by detecting the label. (Item 34) The method according to item 33, wherein the solid tumor cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. (Item 35) The method according to item 33, wherein the solid tumor cancer is pancreatic cancer. (Item 36) The method described in any one of items 33 to 35, wherein the subject has been diagnosed with cancer and is receiving or planning to receive treatment. (Item 37) The method according to item 36, wherein the sample is isolated from the subject before the start of therapy. (Item 38) The method according to item 36, wherein the sample is isolated from the subject after the start of therapy. (Item 39) The method described in any one of items 33 to 38, further comprising repeating steps (a) to (d) at a later point in time. (Item 40) The method according to item 39, wherein the aforementioned later time is after the subject has started therapy. (Item 41) The method according to item 39, wherein the subsequent time point is after the subject has initiated a new or second (co)therapy. (Item 42) The method according to item 40 or 41, wherein the therapy is chemotherapy or radiation. (Item 43) The method according to item 42, wherein the chemotherapy is erlotinib, fluorouracil, or oxaliplatin. (Item 44) The method according to item 40 or 41, wherein the therapy is surgery including Whipple procedure, distal pancreatectomy, and total pancreatectomy, radiotherapy, proton therapy, stereotactic radiotherapy (SBRT) or CyberKnife, immunotherapy, targeted therapy, or chemotherapy. (Item 45) The method according to any one of items 33 to 44, wherein a CEA level is determined, and a higher CEA level at the aforementioned later time point indicates that the therapy is not completely effective, and the same or lower CEA antigen level at the aforementioned later time point indicates that the therapy is at least partially effective. (Item 46) The method described in any one of items 33 to 45, wherein the subject is in a state of remission. (Item 47) The method of item 46, further comprising repeating steps (a) to (d) after the subject has entered a state of remission, wherein the CEA level is determined, a higher CEA level at the later point indicates that the cancer is no longer in remission, and the same or lower CEA level at the later point indicates that the therapy continues to result in at least partial remission. (Item 48) The method according to any one of items 33 to 47, wherein the sample is blood, tissue, or cells, including whole blood, serum, or plasma. (Item 49) The method described in any one of items 33 to 48, wherein the method is an alternative to computed tomography. (Item 50) A method for detecting cancer characterized by the expression of the gene product of CEA and its homologues, comprising: (a) identifying the gene product and its homologues expressed by CEA in a human patient with cancer by isolating a biological sample from a subject, wherein the sample contains the CEA gene product when the CEA gene is expressed; (b) utilizing the gene product as a biomarker by contacting the biological sample with an anti-CEA antibody described in any one of items 1 to 9 or 13 to 15, or a composition described in item 10, to produce a sample-antibody complex; (c) removing any unbound antibody, and then contacting the sample-antibody complex with a label specific to the antibody or the sample-antibody complex; and (d) detecting the presence of the antigen-antibody complex by detecting the label, wherein the detection of the label indicates the detection of cancer. (Item 51) A method for determining the condition of a subject who has cancer, (a) Obtaining a sample from the subject, (b) Contacting the sample with an antibody or antibody fragment described in any one of items 1 to 9 or 13 to 15, or a composition described in item 10, (c) A method comprising determining the amount of CEA detected by the antibody or antibody fragment, wherein positive staining indicates malignant or benign cancer, and negative staining indicates that the cells are not cancerous. (Item 52) A method for detecting pancreatic cancer in a patient, comprising: (a) taking a sample of the pancreas or blood from a patient suspected of having pancreatic cancer or having pancreatic cancer; (b) contacting the sample with an antibody or antibody fragment described in any one of items 1 to 9 or 13 to 15, or a composition described in item 10, thereby forming an antigen-antibody complex in the sample; (c) if the antibody in step (b) is not labeled, labeling the sample with a label specific to the antibody or antigen-antibody complex; (d) detecting the presence of the antigen-antibody complex by detecting the label; and (e) determining the CEA antigen level in comparison with a negative control, wherein a CEA antigen level higher than that of the negative control indicates pancreatic cancer. (Item 53) The method according to item 52, wherein the sample is a pancreas and the negative control is a similar pancreatic sample from a subject that does not have cancer. (Item 54) The method according to item 52, wherein the sample is blood, and the negative control is a blood sample having 0-2.5 ng / mL of CEA when analyzed. (Item 55) The method described above is the method described in item 52, which is performed in vitro. (Item 56) The method according to any one of items 52 to 55, wherein the pancreatic cancer is in an early stage, and the method can detect the CEA antigen in this early stage. (Item 57) The method according to any one of items 52 to 55, wherein the pancreatic cancer is in stage I, II, III, or IV, and the method can detect the CEA antigen in this early stage. (Item 58) A kit for the immunohistochemical detection of pancreatic cancer, comprising: (a) a monoclonal antibody having heavy chain CDR1, CDR2, and CDR3 sequences including SEQ ID NOs. 1, 2, and 3, and light chain CDR1, CDR2, and CDR3 sequences including SEQ ID NOs. 4, 5, and 6, respectively; and (b) a secondary antibody conjugated to a detectable label or a separate unconjugated detectable label, wherein the detectable label or the separate unconjugated detectable label binds to the secondary antibody, the antibody-antigen complex, or the monoclonal antibody in (a). (Item 59) An immunohistochemical method for detecting pancreatic cancer in tissue samples taken from a patient, a) The process of obtaining a tissue sample, b) A step of contacting the tissue specimen with an antibody of an antibody fragment described in any one of items 1 to 9 or 13 to 15, or with a composition described in item 10, c) After step b), the tissue sample is brought into contact with the secondary antibody, the antibody-antigen complex, or a detectable label that binds to the antibody, d) The procedure includes the step of staining the tissue specimen by immunohistochemical staining, An immunohistochemical method wherein the staining indicates the presence of antibody binding and pancreatic cancer in the tissue specimen. (Item 60) A composition comprising a tissue sample and an antibody-antigen complex of an antibody or antibody fragment described in any one of items 1 to 9 or 13 to 15, or a composition described in item 10, wherein the tissue sample is from a patient suffering from cancer. (Item 61) The composition according to item 60, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. (Item 62) Use of the composition described in item 10, or the antibody or antibody fragment described in any one of items 1-9 or 10-13, for the detection of cancer. (Item 63) The composition according to item 62, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. (Item 64) A method for monitoring the progression of cancer and / or the therapeutic effectiveness of cancer drugs, (a) Obtaining initial samples from human patients with cancer at the first time point, (b) Contacting the sample with an antibody or antibody fragment described in any one of items 1 to 9 or 13 to 15, or a composition described in item 10, to form an antigen-antibody complex, (c) Labeling the specimen with a label specific to the antigen-antibody complex, (d) The presence of the antigen-antibody complex is detected by detecting the label, (e) Determining the CEA antigen level detected by the antibody or antibody fragment to determine the baseline level of the CEA antigen associated with the patient's cancer, (f) Obtaining a second sample at a second (later) time point, optionally, such that the second time point is after the period during which the subject is receiving therapy. (g) Repeat steps (b) to (e) to determine the second CEA antigen level associated with the patient's cancer, (h) A method comprising determining that the patient's cancer has progressed if the CEA antigen level at the second time point is higher than the baseline level, and determining that the patient's cancer has regressed if the CEA antigen level at the second time point is lower than the baseline level. (Item 65) The method according to item 64, wherein the cancer is colorectal cancer, liver cancer, stomach cancer, ovarian cancer, thyroid cancer, lung cancer, breast cancer, or pancreatic cancer. (Item 66) The method according to item 64, wherein the solid tumor cancer is pancreatic cancer. (Item 67) The method according to item 64, wherein the increase in CEA at the second time point indicates the progression of the cancer. (Item 68) The method according to item 64, wherein the decrease in CEA at the second time point indicates regression of the cancer. (Item 69) The method according to item 64, wherein the first time point is before therapy or at the time of initial diagnosis. (Item 70) The method according to item 64, wherein the first time point is after therapy or at the time of initial diagnosis. (Item 71) The method described in item 64, wherein the second time point is after the therapy has been administered. (Item 72) The method described above is the method of item 64, performed in vitro. (Item 73) The method according to item 70, wherein the therapy is surgery including Whipple treatment, distal pancreatectomy, and total pancreatectomy, radiotherapy, proton therapy, stereotactic radiotherapy (SBRT) or CyberKnife, immunotherapy, targeted therapy, and chemotherapy.

Claims

1. An isolated anti-cancer embryo antigen (CEA) antibody or its antigen-binding fragment, comprising: (a) HCDR1 containing the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 containing the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 containing the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 containing the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 containing the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 containing the amino acid sequence of SEQ ID NO:

6.

2. The antibody or antigen-binding fragment has a heavy chain variable region (V H ) and light chain variable region (V L ) including the V H However, it includes the amino acid sequences of SEQ ID NO: 7 and SEQ ID NO: 3, and the V L The isolated anti-CEA antibody or antigen-binding fragment according to claim 1, comprising the amino acid sequences of SEQ ID NO: 8 and SEQ ID NO:

6.

3. The isolated anti-CEA antibody or antigen-binding fragment according to claim 2, wherein the antibody or antigen-binding fragment comprises SEQ ID NO: 9 and SEQ ID NO:

10.

4. The antibody is a monoclonal antibody, Fab, Fab', Fv, scFv, or (Fab') 2、 The isolated anti-CEA antibody or antigen-binding fragment according to claim 1, wherein the antibody is a full-length antibody, or the Fc region of the antibody contains IgG1, IgG2, IgG3, IgG4, IgG4.1, or IgG4.2, and / or the isolated antibody or antigen-binding fragment is immobilized on a solid phase, detectably labeled, conjugated to a cytotoxic radionuclide, conjugated to a cytotoxic drug, or conjugated to a cytotoxic protein.

5. A composition comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier.

6. A nucleic acid encoding an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4.

7. The nucleic acid according to claim 6, comprising SEQ ID NO:

11.

8. The nucleic acid according to claim 6, comprising sequence number 12.

9. The nucleic acid according to claim 6, comprising SEQ ID NO: 11 and SEQ ID NO:

12.

10. A vector comprising the nucleic acid described in claim 6.

11. A host cell transformed with the vector described in claim 10.

12. A process for producing an anti-CEA antibody, comprising culturing the host cells described in claim 11 and isolating an anti-CEA antibody molecule.

13. A composition for treating cancer in a person requiring cancer treatment, comprising an anti-CEA antibody according to any one of claims 1 to 4, or comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier, or comprising isolated DNA encoding an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4.

14. A composition for use in an immunoassay for detecting a CEA antigen, comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, wherein the immunoassay comprises (a) contacting a sample with an effective binding amount of the antibody or antigen-binding fragment according to any one of claims 1 to 4, and (b) detecting the binding of the antibody to the CEA antigen, thereby detecting the antigen.

15. A composition for use in a method for detecting cancer in a subject, comprising an anti-CEA antibody according to any one of claims 1 to 4, wherein the method comprises contacting the antibody with a sample isolated from a subject having cancer or a subject suspected of having cancer.

16. A kit for immunohistochemical detection of solid tumors containing cells expressing a CEA antigen, the kit comprising (a) an antibody according to any one of claims 1 to 4, and (b) a secondary antibody conjugated to a detectable label or a separate unconjugated detectable label conjugated to the secondary antibody, wherein the secondary antibody, when bound to the CEA antigen, binds to the antibody of (a) and can be detected.

17. The kit according to claim 16, wherein the cancer is pancreatic cancer.

18. A composition for use in a method for determining the state of solid tumor cancer in a subject, comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, wherein the method comprises (a) taking a sample from a subject having solid tumor cancer; (b) contacting the sample with the antibody or antigen-binding fragment to form a complex of CEA antigen and the antibody or antigen-binding fragment; (c) labeling the sample with a label specific to the antigen-antibody complex; and (d) detecting the presence of the antigen-antibody complex by detecting the label.

19. A composition for use in a method for detecting cancer characterized by the expression of a CEA gene product, comprising an anti-CEA antibody according to any one of claims 1 to 4, or an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier, wherein the method comprises: (a) identifying a gene product expressed by CEA in a human patient with cancer by isolating a biological sample from a subject, wherein the sample contains the CEA gene product when the CEA gene is expressed; (b) utilizing the gene product as a biomarker by contacting the biological sample with the anti-CEA antibody or the composition to produce a sample-antibody complex; (c) removing any unbound antibodies, and then contacting the sample-antibody complex with a label specific to the antibody or the sample-antibody complex; and (d) detecting the presence of the antigen-antibody complex by detecting the label, wherein the detection of the label indicates the detection of cancer.

20. A composition for use in a method for determining the condition of a subject having cancer, comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, or an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier, wherein the method is (a) Obtaining a sample from the subject, (b) Contacting the sample with the antibody or antigen-binding fragment, or the composition, (c) A composition comprising determining the amount of CEA detected by the antibody or antigen-binding fragment, wherein positive staining indicates malignant or benign cancer, and negative staining indicates that the cells are not cancerous.

21. A composition for use in a method for detecting pancreatic cancer in a patient, comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, or an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier, wherein the method comprises: (a) taking a sample of the pancreas or blood from a patient suspected of having pancreatic cancer or having pancreatic cancer; (b) contacting the sample with the antibody or antigen-binding fragment or the composition to form an antigen-antibody complex in the sample; (c) if the antibody in step (b) is not labeled, labeling the sample with a label specific to the antibody or antigen-antibody complex; (d) detecting the presence of the antigen-antibody complex by detecting the label; and (e) determining the CEA antigen level in comparison with a negative control, wherein a CEA antigen level higher than that of the negative control indicates pancreatic cancer.

22. A composition for use in an immunohistochemical method for detecting pancreatic cancer in a tissue sample taken from a patient, comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, or an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier, wherein the method is a) The process of obtaining a tissue sample, b) A step of contacting the tissue specimen with the antibody or antigen-binding fragment, or the composition, c) After step b), the tissue sample is brought into contact with the secondary antibody, the antibody-antigen complex, or a detectable label that binds to the antibody, d) The procedure includes the step of staining the tissue specimen by immunohistochemical staining, A composition in which the staining indicates antibody binding and the presence of pancreatic cancer in the tissue specimen.

23. A composition for use in a method for monitoring the progression of cancer and / or the therapeutic effect of cancer drugs, comprising an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, or an anti-CEA antibody or antigen-binding fragment according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier, wherein the method (a) Obtaining initial samples from human patients with cancer at the first time point, (b) Contacting the sample with the antibody or antigen-binding fragment, or the composition, thereby forming an antigen-antibody complex, (c) Labeling the specimen with a label specific to the antigen-antibody complex, (d) The presence of the antigen-antibody complex is detected by detecting the label, (e) Determining the CEA antigen level detected by the antibody or antigen-binding fragment to determine the baseline level of the CEA antigen associated with the patient's cancer, (f) Obtaining a second sample at a second (later) time point, wherein the second time point is after the period during which the subject is receiving therapy, (g) Repeat steps (b) to (e) to determine the second CEA antigen level associated with the patient's cancer, (h) A composition comprising determining that the patient's cancer has progressed if the CEA antigen level at the second time point is higher than the baseline level, and determining that the patient's cancer has regressed if the CEA antigen level at the second time point is lower than the baseline level.

Citation Information

Patent Citations

  • Anti-ceacam5 antibodies and uses thereof

    JP2016506370A